Rajeshwar P Mookerjee1. 1. UCL Institute of Hepatology, Royal Free Campus, London, UK. r.mookerjee@ucl.ac.uk
Abstract
PURPOSE OF REVIEW: During acute-on-chronic liver failure (ACLF), the marked systemic inflammatory response and rapid deterioration in liver function are associated with a significant deterioration in organ perfusion and an appreciable rise in portal pressure. Indeed, the development of sepsis and multiorgan dysfunction that commonly follows presentation in these patients is intricately related to the severity of portal hypertension. It follows that understanding the drivers for rising portal pressure in ACLF will inform new therapies. RECENT FINDINGS: As this review aims to highlight, there has been a paradigm shift in understanding of the drivers of portal hypertension, from a prior focus on splanchnic vasodilatation and therapies targeting portal inflow, toward appreciation of increasing intrahepatic resistance as the trigger for further vascular derangement, especially in the context of systemic inflammatory responses. SUMMARY: By elaborating on those mechanisms that are especially perturbed by inflammatory responses, this article aims to show how this understanding has helped inform the identification of potential new targets for therapy in ACLF. Particular emphasis is given to agents with data supporting their progression toward clinical trials and those currently undergoing validation in clinical studies.
PURPOSE OF REVIEW: During acute-on-chronic liver failure (ACLF), the marked systemic inflammatory response and rapid deterioration in liver function are associated with a significant deterioration in organ perfusion and an appreciable rise in portal pressure. Indeed, the development of sepsis and multiorgan dysfunction that commonly follows presentation in these patients is intricately related to the severity of portal hypertension. It follows that understanding the drivers for rising portal pressure in ACLF will inform new therapies. RECENT FINDINGS: As this review aims to highlight, there has been a paradigm shift in understanding of the drivers of portal hypertension, from a prior focus on splanchnic vasodilatation and therapies targeting portal inflow, toward appreciation of increasing intrahepatic resistance as the trigger for further vascular derangement, especially in the context of systemic inflammatory responses. SUMMARY: By elaborating on those mechanisms that are especially perturbed by inflammatory responses, this article aims to show how this understanding has helped inform the identification of potential new targets for therapy in ACLF. Particular emphasis is given to agents with data supporting their progression toward clinical trials and those currently undergoing validation in clinical studies.
Authors: Sara Blasco-Algora; José Masegosa-Ataz; María Luisa Gutiérrez-García; Sonia Alonso-López; Conrado M Fernández-Rodríguez Journal: World J Gastroenterol Date: 2015-11-14 Impact factor: 5.742
Authors: Yohannes T Ghebremariam; Keisuke Yamada; Jerry C Lee; Christine L C Johnson; Dorothee Atzler; Maike Anderssohn; Rani Agrawal; John P Higgins; Andrew J Patterson; Rainer H Böger; John P Cooke Journal: PLoS One Date: 2013-04-04 Impact factor: 3.240
Authors: Nowlan Selvapatt; Arjuna Singanayagam; Julia Wendon; Charalambos Gustav Antoniades Journal: Intensive Care Med Date: 2014-06-06 Impact factor: 17.440
Authors: Manil D Chouhan; Alan Bainbridge; David Atkinson; Shonit Punwani; Rajeshwar P Mookerjee; Mark F Lythgoe; Stuart A Taylor Journal: Phys Med Biol Date: 2016-12-21 Impact factor: 3.609